Long-term efficacy and safety of Control-IQ technology in younger children with type 1 diabetes in Italy (2020–2023): a longitudinal multicentre real-world study

Read full text
Authors: Valentino Cherubini, Roberto Franceschi, Andrea Fargalli, Marta Bassi, Riccardo Bonfanti, Giulia Bracciolini, Barbara Felappi, Riccardo Foglino, Dario Iafusco, Anna Lasagni, Bruno Bombaci, Claudio Maffeis
+34 more Giulio Maltoni, Chiara Mameli, Enza Mozzillo, Nicola Minuto, Barbara Piccini, Lara Devilli, Giulia Pezzino, Carmelo Pistone, Elena Prandi, Ivana Rabbone, Andrea Scaramuzza, Sara Santarelli, Francesca Silvestri, Riccardo Schiaffini, Valentina Tiberi, Davide Tinti, Marco Marigliano, Rosaria Gesuita, Donatella Lo Presti, Elvira Piccinno, Francesca Franco, Valeria Donno, Petra Reinstadler, Silvia Sordelli, Vanna Graziani, Rosalia Roppolo, Anna Lambertini, Barbara Predieri, Emioli Randazzo, Elisabetta Delduca, Benedetta Vestrucci, Marilea Lezzi, Maurizio Delvecchio, Antonio Iannilli
Cited by: 2
References: 23

Abstract

Background: Automated insulin delivery (AID) systems have demonstrated significant improvements in glycemic control in children and adults with type 1 diabetes, but long-term real-world data in preschool-aged children remain limited, particularly in Europe, where Control-IQ is not approved for children under 6 years. This study aimed to evaluate the long-term effectiveness and safety of the t:slim X2 insulin pump with Control-IQ technology in children aged 0.5-5 years compared with those aged 6-10 years in a real-world multicenter Italian cohort. Methods: In this longitudinal, observational study conducted from 2020 to 2023, data were collected from 32 Italian centers on children

Fields of Study & Subjects

Diabetes Management and Research Mobile Health and mHealth Applications Pancreatic function and diabetes

Publication details

Journal / source
EClinicalMedicine
Publisher
Elsevier BV
Volume
93
Pages
103829–103829
Publication date
1 March 2026
Language
EN